Using a high-throughput informatics technique and electronic health records, Vanderbilt researchers found that COVID-19 survivors had an increased risk for more than 40 new diagnoses.

Vanderbilt University Medical Center has received a five-year, $4.5 million grant from the National Human Genome Research Institute to assess clinical outcomes and economic value of screening large, diverse health care populations for disease risk using polygenic risk scores.

When a drug or combination of drugs causes different responses in different people, genetic variation is often at play. Pharmacogenomics, through discovery of genetic risk and use of clinical genotyping, aims to reduce trial-and-error approaches to drug prescribing.

Population-wide screening for genetic variants linked to hereditary breast and ovarian cancer may be cost effective in women between the ages of 20 and 35, according to a study published in JAMA Network Open.

With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants’ relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes.

Out of the electronic health records (EHRs) of patients seen at Vanderbilt University Medical Center, a team in the Department of Biomedical Informatics is creating a COVID-19 patient registry as a platform for research.

Josh Peterson, MD, MPH, and Dan Roden, MD, are among 10 leaders in clinical pharmacology and translational medicine recognized this week by the American Society for Clinical Pharmacology and Therapeutics.